The main strengths of this study include the simultaneous measurement of multiple plasma tau species in a single analysis, allowing us to identify which biomarkers are most effective for staging AD and to develop a staging system that reflects various pathological changes. This evidence concerns the gene MAPT and Alzheimer disease.